Non-epithelioid

Non-epithelioid is a category used by pathologists to describe mesothelioma tumors that are not the epithelioid subtype. It includes the sarcomatoid subtype (spindle-shaped cells resembling connective tissue tumors) and the biphasic subtype (a mixture of epithelioid and sarcomatoid cells). Non-epithelioid mesotheliomas generally carry a more aggressive course and respond less well to standard chemotherapy than purely epithelioid tumors.

Origin

The term combines the prefix "non-" with "epithelioid," from the Greek epi- (upon) and thele (nipple/covering), referring to epithelial-like tissue. The histologic subtyping of mesothelioma into epithelioid, sarcomatoid, and biphasic forms was formalized in the mid-20th century and has been refined in successive World Health Organization classifications, most recently the 2021 WHO Classification of Thoracic Tumours.

Significance in Asbestos Context

For a patient, learning that a mesothelioma is non-epithelioid is one of the most important prognostic facts in the pathology report. It typically means shorter median survival and a different treatment conversation. Surgical options such as pleurectomy/decortication or extrapleural pneumonectomy are often more limited or not offered for non-epithelioid tumors, and immunotherapy combinations (such as nivolumab plus ipilimumab) have shown particular benefit in this group compared with traditional chemotherapy. In medical records and expert reports used in a legal claim, the non-epithelioid designation will shape both the projected life expectancy used to calculate damages and the urgency of moving the case forward.

Example Sentence

When the biopsy came back as non-epithelioid mesothelioma, the oncologist recommended starting immunotherapy quickly and referred the family to a specialist center for a second opinion.

Related Terms

Epithelioid Mesothelioma, Sarcomatoid Mesothelioma, Biphasic Mesothelioma, Immunohistochemistry, Histologic Subtype, Prognosis

Notes

• Ask the pathologist or oncologist for the exact percentage of sarcomatoid component, as even small sarcomatoid features within an otherwise epithelioid tumor change prognosis and treatment planning.
• Request that diagnostic slides and tissue blocks be preserved and consider seeking a second pathology review at a mesothelioma specialty center (such as an NCI-designated cancer center). Subtype misclassification is not uncommon.
• Discuss whether immunotherapy (checkpoint inhibitors) is appropriate as first-line therapy, since non-epithelioid mesothelioma has historically responded poorly to pemetrexed/cisplatin chemotherapy alone.
• Preserve the full pathology report, immunohistochemistry results, and any molecular testing. These documents are central both to treatment decisions and to establishing diagnosis and prognosis in a legal claim.